Dynamic range expansion of spatial light modulators based on a module-nπ method.

It is known that the cumbersome 2π correction is needed in the traditional module-2π method (i.e., the phase wrapping method) due to the 2π deviation of the phase modulation depth of spatial light modulators (SLMs). To avoid the cumbersome 2π correction in the module-2π method, this paper proposes a module-n π method, and it can directly utilize any full-field phase modulation depth. First, for a Gaussian phase with a phase depth of 30 rad, wrapped by the module-3.6π, it is reconstructed with the root-mean-square (RMS) values of its phase response are 0.1006λ (for the Twyman-Green interferometer) and 0.1101λ (for the Shack-Hartmann wavefront sensor method), respectively, which proves that the monitoring accuracy is relatively consistent. Subsequently, some comparative experiments based on the traditional module-2π are performed. The experimental results show that the RMS values of its phase response are 0.8886λ (for a modulation depth of 11.3 rad) and 0.2261λ (for a modulation depth of 6.28 rad), respectively. All the results have proved that the SLM with a phase modulation depth exceeding 2π (e.g., 11.3 rad) has more prominent advantages. More specifically, increasing the SLM's phase modulation depth can effectively reduce the fringe orders of the wrapped patterns generated by the module-n π method. With the further reduction of the fringe orders, the influence of the fly-back zone error on the wavefront phase modulation is reduced, that is, the modulation accuracy is improved (the RMS values are reduced from 0.2261λ to 0.1006λ). Different from the traditional module-2π method, there is no need to consider the problems of the SLMs' over modulation or the insufficient modulation in the module-n π method. Furthermore, it avoids the cumbersome 2π correction process, which will make the use of the SLM more convenient.

The function of long noncoding RNA HOTAIRM1 in the progression of prostate cancer cells.

Emerging evidence is indicating the importance of hundreds of long noncoding RNAs (lncRNAs) in the occurrence and progression of different malignancies such as prostate cancer (PCa). This study investigated the possible role of HOX transcript antisense intergenic RNA myeloid-specific 1 (HOTAIRM1) in the progression of tumorigenesis of PC3 as PCa cell line. RT-qPCR was used to measure HOTAIRM1 expression levels in PC3 and RWPE-1 cell lines. To detect the effect of HOTAIRM1 in the progression of PCa, HOTAIRM1 was silenced on PC3 cells with specific siRNA and transfected into cells using a liposomal approach. Using MTT assay, the effects of si-HOTAIRM1 on cell viability and proliferation were evaluated. Cell apoptosis was analysed using flow cytometry and Wnt pathway-related proteins by Western blot. HOTAIRM1 was overexpressed in PC3 cells compared with RWPE-1 cells. Reducing HOTAIRM1 alleviated cell proliferation and increased apoptosis of PC3 cells so that the expression of pro-apoptotic agents such as Bad and Bax was significantly increased, while that of Bid and Bcl-2 (anti-apoptotic) was decreased. Furthermore, HOTAIRM1 silencing suppressed the Wnt pathway. Overall, HOTAIRM1 silencing in PC3 cells inhibited the proliferative ability and promoted the apoptosis of PCa cells by suppressing the Wnt pathway, thereby inhibiting the progression of PCa.

The Effects of (11R)-13-(6-Nitroindazole)-11,13-Dihydroludartin on Human Prostate Carcinoma Cells and Mouse Tumor Xenografts.

BACKGROUND This study aimed to investigate the effects of the 6-nitroindazole compound and amino analog of ludartin, (11R)-13-(6-nitroindazole)-11,13-dihydroludartin (NDHL), on human prostate carcinoma cells in vitro and in mouse tumor xenografts in vivo. MATERIAL AND METHODS DU-145 and LNCaP human prostate carcinoma cells were cultured with increasing concentrations of NDHL. Cell viability was measured using the MTT assay, and cell apoptosis was measured by fluorescence flow cytometry. Mouse tumor xenografts were created by implanting 2×106 of DU-145 cells subcutaneously in the left flank. On the second day following DU-145 cell implantation, the mice in the treatment groups were injected intraperitoneally with 2, 5, and 10 mg/kg of NDHL. RESULTS Treatment of DU-145 and LNCaP cells with NDHL (range, 2.5-20.0 µM) significantly reduced cell proliferation in vitro (P<0.05). The proliferation rate of DU-145 and LNCaP cells was reduced to 27% and 24%, respectively, following treatment with 20.0 µM of NDHL. Treatment with NDHL significantly increased cell apoptosis and the formation of reactive oxygen species (ROS) formation in DU-145 cells at 48 h (P<0.05). NDHL significantly increased the proportion of DU-145 cells in the G1 phase of the cell cycle and significantly increased the expression of cyclin D1 and p21 (P<0.05). Treatment of the mice in the xenograft tumor model with NDHL significantly increased survival and suppressed tumor growth (P<0.02). CONCLUSIONS NDHL inhibited cell proliferation, increased apoptosis, and caused cell cycle arrest in human prostate carcinoma cells in vitro and inhibited mouse tumor xenograft growth in vivo.

[Efficacy of compound xuanju capsule on type-III prostatitis-related sexual dysfunction].

OBJECTIVE: To investigate the value of Compound Xuanju Capsule in the treatment of type-III prostatitis-related sexual dysfunction. METHODS: We randomly divided 90 type-III prostatitis patients with sexual dysfunction diagnosed by NIH clinical criteria into an experiment group and a control group to be treated with Compound Xuanju Capsule and antibiotics, respectively. We analyzed the therapeutic results based on the scores on chronic prostatitis symptom index (CPSI), prostatitis-related sexual function index (PSFI ) and self-rating anxiety scale (SAS), and compared them between the two groups and with the baseline data. RESULTS: The degree of prostatitis-related sexual dysfunction was not correlated with that of prostatitis symptoms. Prostatitis symptoms and sexual function were significantly improved in the experiment group than in the control (P < 0.05), and the SAS score was markedly lower in the former than in the latter (P < 0.05). CONCLUSION: Compound Xuanju Capsule can not only alleviate the symptoms of type-III prostatitis, but also improve its related sexual dysfunction and anxiety.